{"url":"https://lda.senate.gov/api/v1/filings/f0f621c3-7532-4264-a92d-e5f40ff50dcd/","filing_uuid":"f0f621c3-7532-4264-a92d-e5f40ff50dcd","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2022,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.senate.gov/filings/public/filing/f0f621c3-7532-4264-a92d-e5f40ff50dcd/print/","filing_document_content_type":"text/html","income":null,"expenses":"120000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"John Martin","dt_posted":"2022-07-14T14:54:50-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2173 SALK AVE., SUITE 250","registrant_address_2":"PMB #052","registrant_different_address":false,"registrant_city":"Carlsbad","registrant_state":"CA","registrant_zip":"92008","registrant":{"id":401106493,"url":"https://lda.senate.gov/api/v1/registrants/401106493/","house_registrant_id":45529,"name":"PARDES BIOSCIENCES, INC.","description":null,"address_1":"2173 SALK AVE., SUITE 250","address_2":"PMB #052","address_3":null,"address_4":null,"city":"Carlsbad","state":"CA","state_display":"California","zip":"92008","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOHN MARTIN","contact_telephone":"+1 817-713-5206","dt_updated":"2024-05-01T13:00:26.504638-04:00"},"client":{"id":45950,"url":"https://lda.senate.gov/api/v1/clients/45950/","client_id":45950,"name":"PARDES BIOSCIENCES, INC.","general_description":"Developing oral anti-virals for COVID-19 and other Pan-coronaviruses.","client_government_entity":null,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-01-31"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"COVID Oral antivirals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138389,"prefix":"mr","prefix_display":"MR.","first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":"Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton","new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Covid Oral Anti Virals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138389,"prefix":"mr","prefix_display":"MR.","first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":"Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"COVID Oral Antivirals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138389,"prefix":"mr","prefix_display":"MR.","first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":"Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton","new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":21,"name":"Office of Science & Technology Policy (OSTP)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"COVID Oral Antivirals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138389,"prefix":"mr","prefix_display":"MR.","first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"MARTIN","suffix":null,"suffix_display":null},"covered_position":"Principal Associate Commissioner, FDA Legislative Affairs, Sen. Tom Cotton","new":false}],"government_entities":[{"id":139,"name":"Natl Institutes of Health (NIH)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}